Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies

2 Apr 2013

Product news

Leica Biosystems and Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, today announced an agreement to collaborate on the development and commercialization of a companion diagnostic test using the Leica BOND system, paired with one of Synthon Biopharmaceutical’s antibody-drug conjugates (ADCs), to enhance the treatment of solid tumors.

“We are pleased to be working with Synthon Biopharmaceuticals on cancer therapies with the Leica BOND platform,” added Matthias Weber, President of Leica Biosystems, MD. “This partnership with Synthon is the next example of our commitment to provide unique tests to support the management of cancer patients. The ease of use and high staining quality of our BOND systems makes them ideal platforms on which to deploy these very informative tests”.

Dr. Leon Hooftman, Chief Medical Officer at Synthon, comments: “Synthon is committed to develop a best-in-class ADC. This collaboration with Leica Biosystems will support us in delivering on that ambition.”

Links

Tags

Cellular PathologyCellular Pathology deals with the microscopic analysis of tissue samples and cells. Sample preparation and processing includes fixation, staining, sectioning and slide mounting, using equipment such microtomes and cryostats. In choosing immunohistochemistry and immunocytochemistry kits, consider chromogens, staining method, antibodies, microscopes and imaging.Companion DiagnosticsCompanion diagnostics are tests, often <i>in vitro</i>, that are used to determine whether a therapeutic product will be safe and effective for use on an individual. They also identify which patients will benefit most from them. Companion diagnostic tests are often developed in conjunction with the pharmaceutical industry.ImmunohistochemistryImmunohistochemistry (IHC) is a technique used to detect specific proteins in tissue samples by using antibodies that bind to target antigens. IHC is widely applied in pathology, immunology, hematology and cancer diagnostics. Explore IHC tools in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Histology ProcessingCancer ResearchAlthough cancer is often referred to as a single condition, it actually consists of more than 100 different diseases. Microscopy, mass spectrometry, high throughput sequencing and flow cytometry are some of the most common techniques employed in cancer research labs.Cancer DiagnosticsThere are a wide variety of diagnostic tests for cancer available, and this range continues to expand as our knowledge of cancer improves. Current diagnostic methods include biopsy, imaging and blood tests for known biomarkers. New methods in research development include liquid biopsies and cancer breathalyzers.
Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies